Cardior Pharmaceuticals

Next Generation RNA based Cardiovascular Medicine

Cardior wins second prize at the BioVaria 2015 Spin-Off Panel

"The second prize, a [Pinsent Masons] start-up consulting package, went to Cardior Pharmaceuticals, a spin-off project from Hannover Medical School headed by Prof. Thomas Thum. He is developing an innovative oligonucleotide inhibitor to improve heart function and prevent heart failure." Press Release
Watch Thomas's Pitch and Q&A

TIDES Meeting 2015 - Best Poster Presentation Award goes to Presentation by Cardior Co-Founder

Sandor received the 2015 Poster Award at the Oligonucleotide and Peptide Therapeutics Conference (TIDES) that took place May 3-6 in San Diego, California. He presented data on Cardior's core technology: “Therapeutic oligonucleotide-based inhibition of miR-132 as novel treatment of chronic heart failure”.
The Poster Award of the conference recognizes presenters whose research efforts demonstrate exceptional advances and breakthroughs in the areas of discovery, pre-clinical and clinical aspects of oligonucleotide based therapeutic research. The prize was accompanied by an award of $12,500 in in-kind support from the sponsor, AUM LifeTech, Inc.